Northwestern University Feinberg School of Medicine
Skip to main content
Jamile M Shammo

Jamile M Shammo

Dr. Marjorie C. Barnett - Dr. Hau C. Kwaan Professor

Professor, Medicine (Hematology and Oncology)

 Edit My Profile
Become a Media Expert

Jamile M Shammo leads the following active clinical trials that are recruiting research participants/patients. Find all Feinberg Clinical Trials.

ETCTN 10538: Venetoclax In Combination with ASTX727, an All-ORal TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial

…
More Info
Copy Study URL to Clipboard Copy

(xIRB) DRUG INCB 160058-101: A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms (LIMBER-101)

This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms. Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.…
More Info
Email Howells, Emily J Phone 312 695 1102
Copy Study URL to Clipboard Copy

Jamile M Shammo, MD reported the external professional relationships noted below for calendar year 2023.

Industry Relationships

Consulting / Related Activities

Faculty member engaged in activities such as speaking, advising, consulting, or providing educational programs for the following companies or other entities
  • Academy for Continued Healthcare Learning, LLC
  • Alexion Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • Blueprint Medicines Corporation
  • Bristol-Myers Squibb Company
  • CTI BioPharma Corp.
  • GlaxoSmithKline (GSK)
  • IQVIA
  • Incyte Corporation
  • MJH Life Sciences
  • Novartis
  • Plexus Communications
  • Protagonist Therapeutics Inc.
  • Sanofi Genzyme

Ownership or Investment Interests

Faculty member had an ownership or investment interest in the following companies
  • AbbVie, Inc.

External Professional Relationships

Pharmaceutical, device, and biotechnology companies frequently collaborate with basic scientists and physicians within an academic medical center to help advance science and improve patient care. These relationships are important in achieving scientific breakthroughs and in establishing the effectiveness and safety of promising new therapies. In order to assure objectivity in clinical research and patient care, the Northwestern University Feinberg School of Medicine (Feinberg), Northwestern Memorial HealthCare, Children's Hospital of Chicago Medical Center, and the Shirley Ryan AbilityLab have adopted integrity policies that require research and clinical faculty (in full-time, part-time, and unpaid/voluntary categories) to report compensated and uncompensated external industry relationships. Patients are encouraged to discuss these disclosures with their physician as well as to inquire as to how these relationships are overseen by Feinberg. To learn more about our Disclosure and Professional Integrity Policy, and the conflict of interest policies of our joint affiliate survey partners, please go to our Office for Regulatory Affairs Policies page.

Feinberg will provide yearly disclosure updates to each faculty member’s profile. Please note there may be some discrepancies between this and other public sites as a result of different reporting periods or categorization of relationships. In addition, conference management, educational, and similar organizations may provide compensation to physicians on behalf of pharmaceutical, device, and biotechnology companies. If patients would like additional information regarding their physician’s relationships with these organizations, they should contact their physician directly.

Please click this link to submit Disclosure Feedback.